{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:33:07Z","timestamp":1787657587184,"version":"build-2736575974"},"reference-count":26,"publisher":"Wiley","issue":"17","license":[{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007136","name":"Karyopharm Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007136","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In lung cancer, overexpression of nuclear export proteins can result in inactivation of critical tumor suppressor proteins and cell\u2010cycle regulators. Selective suppression of nuclear export proteins has immunomodulatory activities. Here, clinical safety and early efficacy data are presented on the combination of pembrolizumab and an oral selective nuclear export inhibitor, selinexor, for the treatment of metastatic non\u2013small cell lung cancer (mNSCLC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The primary objective of this prospective investigator\u2010initiated study was to determine the safety and tolerability of selinexor in combination with pembrolizumab in patients with mNSCLC. Secondary objectives included determination of objective tumor response rate, disease control rate, and progression\u2010free survival duration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 17 patients were included in the final analysis. Fifteen (88%) received more than two lines of prior systemic therapy and 10 (59%) had prior exposure to anti\u2013PD\u20101\/programmed death\u2010ligand 1 (PD\u2010L1) therapy. The median age was 67.5\u00a0years. Ten patients had grade \u22653 adverse events related to selinexor treatment. Responses to treatment occurred in patients who did and did not undergo previous anti\u2013PD\u20101\/PD\u2010L1 therapy and in patients with activating driver mutations. The median overall survival and progression\u2010free survival were 11.4\u00a0months (95% CI, 3.4\u201319.8\u00a0months) and 3.0\u00a0months (95% CI, 1.7\u20135.7\u00a0months), respectively. The overall response rate was 18% and the 6\u2010month disease control rate was 24%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Selinexor in combination with pembrolizumab demonstrated promising antitumor activity in patients with mNSCLC, including those who had previously received anti\u2013PD\u20101\/PD\u2010L1 therapy. The therapy\u2010related toxic effects were consistent with the prior safety data for both drugs, and no overlapping toxic effects were observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link> identifier: NCT02419495.<\/jats:p><\/jats:sec><jats:sec><jats:title>Plain language summary<\/jats:title><jats:p>\n<jats:list list-type=\"bullet\">\n<jats:list-item><jats:p>New strategies to prevent or reverse resistance to immune checkpoint inhibitors are under investigation. Selective inhibitors of nuclear export proteins, such as selinexor, can induce restoration of tumor\u2010suppressing pathways and induce potent immunomodulatory activities.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>This article contains the clinical safety and early efficacy data on the combination of pembrolizumab and selinexor in treatment of metastatic non\u2013small cell lung cancer.<\/jats:p><\/jats:list-item>\n<\/jats:list>\n<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.34820","type":"journal-article","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T07:34:14Z","timestamp":1683012854000},"page":"2685-2693","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non\u2013small cell lung cancer"],"prefix":"10.1002","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9229-156X","authenticated-orcid":false,"given":"Mehmet","family":"Altan","sequence":"first","affiliation":[{"name":"Department of Thoracic\/Head and Neck Medical Oncology The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1899-3501","authenticated-orcid":false,"given":"Janet","family":"Tu","sequence":"additional","affiliation":[{"name":"Department of Thoracic\/Head and Neck Medical Oncology The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Den\u00e1i R.","family":"Milton","sequence":"additional","affiliation":[{"name":"Department of Biostatistics The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bulent","family":"Yilmaz","sequence":"additional","affiliation":[{"name":"Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Tian","sequence":"additional","affiliation":[{"name":"Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank V.","family":"Fossella","sequence":"additional","affiliation":[{"name":"Department of Thoracic\/Head and Neck Medical Oncology The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank E.","family":"Mott","sequence":"additional","affiliation":[{"name":"Department of Thoracic\/Head and Neck Medical Oncology The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George R.","family":"Blumenschein","sequence":"additional","affiliation":[{"name":"Department of Thoracic\/Head and Neck Medical Oncology The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1653-2012","authenticated-orcid":false,"given":"Bettzy","family":"Stephen","sequence":"additional","affiliation":[{"name":"Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Karp","sequence":"additional","affiliation":[{"name":"Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6816-6072","authenticated-orcid":false,"given":"Funda","family":"Meric\u2010Bernstam","sequence":"additional","affiliation":[{"name":"Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John V.","family":"Heymach","sequence":"additional","affiliation":[{"name":"Department of Thoracic\/Head and Neck Medical Oncology The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4803-8513","authenticated-orcid":false,"given":"Aung","family":"Naing","sequence":"additional","affiliation":[{"name":"Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,5,2]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2149"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.can\u201008\u20100858"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1274"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature19771"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2011.12.016"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010020\u201000903\u20104"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.can\u201009\u20100484"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.65.3949"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101179"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/2767\u20109764.crc\u201021\u20100176"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419\u2010019\u20101627\u20109"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2021.01.008"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.260"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19285"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010020\u201000903\u20104"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535\u20107163.mct\u201013\u20100416"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535\u20107163.mct\u201016\u20100498"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538\u20107445.am2016\u2010lb\u2010086"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538\u20107445.am2022\u20105519"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010020\u20100756\u20106"},{"key":"e_1_2_10_22_1","unstructured":".https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010\u201006\u201014_QuickReference_8.5x11.pdf. Accessed April 20 2022."},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.11.004"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.1247"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00912"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.01.151"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.34820","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T21:19:52Z","timestamp":1760303992000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.34820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,2]]},"references-count":26,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1002\/cncr.34820"],"URL":"https:\/\/doi.org\/10.1002\/cncr.34820","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,2]]},"assertion":[{"value":"2022-09-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}